Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions

被引:7
|
作者
Lu, Zhiyuan [1 ]
Suzuki, Ayako [2 ,3 ]
Wang, Dong [1 ]
机构
[1] US FDA, Natl Ctr Toxicol Res, Div Bioinformat & Biostat, Jefferson, AR 72079 USA
[2] Duke Univ, Div Gastroenterol, Durham, NC USA
[3] Durham VA Med Ctr, Dept Med, Durham, NC USA
关键词
Drug-host factor interactions; Likelihood ratio tests; FAERS; Postmarket surveillance; Spontaneous reporting adverse event databases; SIGNAL-DETECTION; RATIO; FREQUENCY; GENDER;
D O I
10.1186/s12874-023-01885-w
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundDrug toxicity does not affect patients equally; the toxicity may only exert in patients who possess certain attributes of susceptibility to specific drug properties (i.e., drug-host interaction). This concept is crucial for personalized drug safety but remains under-studied, primarily due to methodological challenges and limited data availability. By monitoring a large volume of adverse event reports in the postmarket stage, spontaneous adverse event reporting systems provide an unparalleled resource of information for adverse events and could be utilized to explore risk disparities of specific adverse events by age, sex, and other host factors. However, well-formulated statistical methods to formally address such risk disparities are currently lacking.MethodsIn this paper, we present a statistical framework to explore spontaneous adverse event reporting databases for drug-host interactions and detect risk disparities in adverse drug events by various host factors, adapting methods for safety signal detection. We proposed four different methods, including likelihood ratio test, normal approximation test, and two tests using subgroup ratios. We applied our proposed methods to simulated data and Food and Drug Administration (FDA) Adverse Event Reporting Systems (FAERS) and explored sex-/age-disparities in reported liver events associated with specific drug classes.ResultsThe simulation result demonstrates that two tests (likelihood ratio, normal approximation) can detect disparities in adverse drug events associated with host factors while controlling the family wise error rate. Application to real data on drug liver toxicity shows that the proposed method can be used to detect drugs with unusually high level of disparity regarding a host factor (sex or age) for liver toxicity or to determine whether an adverse event demonstrates a significant unbalance regarding the host factor relative to other events for the drug.ConclusionThough spontaneous adverse event reporting databases require careful data processing and inference, the sheer size of the databases with diverse data from different countries provides unique resources for exploring various questions for drug safety that are otherwise impossible to address. Our proposed methods can be used to facilitate future investigation on drug-host interactions in drug toxicity using a large number of reported adverse events.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Exploring the impact of co-exposure timing on drug-drug interactions in signal detection through spontaneous reporting system databases: a scoping review
    Cocco, Marianna
    Carnovale, Carla
    Clementi, Emilio
    Barbieri, Maria Antonietta
    Battini, Vera
    Sessa, Maurizio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (5-6) : 441 - 453
  • [22] Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases
    Mukai, Ririka
    Hasegawa, Shiori
    Umetsu, Ryogo
    Nakao, Satoshi
    Shimada, Kazuyo
    Uranishi, Hiroaki
    Masuta, Mayuko
    Suzuki, Honami
    Nishibata, Yuri
    Nakamura, Mitsuhiro
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (02) : 285 - 291
  • [23] Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
    Nagai, Junko
    Ishikawa, Yoichi
    PLOS ONE, 2021, 16 (12):
  • [24] Analysis of Clinical Factors in Olaparib-related Anemia Using Adverse Drug Event Reporting Databases
    Shiraishi, Chihiro
    Hirai, Toshinori
    Ogura, Toru
    Iwamoto, Takuya
    ANTICANCER RESEARCH, 2023, 43 (02) : 883 - 891
  • [25] Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database
    Magro, Lara
    Arzenton, Elena
    Leone, Roberto
    Stano, Marilisa Giustina
    Vezzaro, Michele
    Rudolph, Annette
    Castagna, Irene
    Moretti, Ugo
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [26] Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases
    Niels S. Vermeer
    Sabine M. J. M. Straus
    Aukje K. Mantel-Teeuwisse
    Francois Domergue
    Toine C. G. Egberts
    Hubert G. M. Leufkens
    Marie L. De Bruin
    Drug Safety, 2013, 36 : 617 - 625
  • [27] Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases
    Vermeer, Niels S.
    Straus, Sabine M. J. M.
    Mantel-Teeuwisse, Aukje K.
    Domergue, Francois
    Egberts, Toine C. G.
    Leufkens, Hubert G. M.
    De Bruin, Marie L.
    DRUG SAFETY, 2013, 36 (08) : 617 - 625
  • [28] Effect of well established drug-event associations on the generation of new signals in spontaneous reporting databases
    Pariente, A.
    Avillach, P.
    Thiessard, F.
    Miremont-Salame, G.
    Fourrier-Reglat, A.
    Haramburu, F.
    Moore, N.
    DRUG SAFETY, 2007, 30 (10) : 924 - 924
  • [29] Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting
    Linder, Jeffrey A.
    Haas, Jennifer S.
    Iyer, Aarthi
    Labuzetta, Michael A.
    Ibara, Michael
    Celeste, Michael
    Getty, George
    Bates, David W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (12) : 1211 - 1215
  • [30] Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases
    Park-Wyllie, Laura
    van Stralen, Judy
    Castillon, Genaro
    Sherman, Stephen E.
    Almagor, Doron
    CLINICAL THERAPEUTICS, 2017, 39 (10) : 2006 - 2023